Results 81 to 90 of about 349 (107)

Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care? [PDF]

Expert Opin Pharmacother
Johnston EK, Bird EM, Malhotra A, Harding CD.   +3 more
europepmc   +1 more source

Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes. [PDF]

Front Endocrinol (Lausanne)
Islam MS, Monir SB, Haque N, Vabna MA, Fan J, Li Y, Nime I, Feroz F, Acharjee M, Pan F.   +9 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects. [PDF]

J Pers Med
Buonanno S, Gaggiano C, Baldi C, Cantarini L, Frediani B, Gentileschi S.   +5 more
europepmc   +1 more source

CagriSema: a novel dual-pathway approach to target obesity and its complications

Metabolism and Target Organ Damage
Amaia Rodríguez, Gema Frühbeck
exaly   +3 more sources

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Lancet Diabetes and Endocrinology,the
Richard E. Pratley, Chantal Mathieu, Torquil Watt   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

CagriSema and the link between obesity and type 2 diabetes

Lancet, The, 2023
Marie E McDonnell, Caroline M. Apovian
exaly   +3 more sources

1695-P: Effect of CagriSema on Eating Control and Behavior: REDEFINE 1

Diabetes
Introduction and Objective: We assessed the effect of CagriSema on eating control and behavior in adults with overweight/obesity. Methods: In REDEFINE 1 (NCT05567796), 3417 adults (67.6% female; mean: age, 47.0 years; body weight, 106.9 kg; BMI, 37.9 kg/m2) were randomized 21:3:3:7 to once-weekly CagriSema 2.4 mg/2.4 mg (n=2108 ...
Matthias Blüher
exaly   +2 more sources

1035-OR: Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity

Diabetes
Introduction and Objective: CagriSema (fixed-dose combination of semaglutide 2.4 mg and cagrilintide 2.4 mg) is currently under development for weight management and type 2 diabetes. This clinical pharmacology study aimed to investigate the CagriSema effects on appetite, eating behavior, and brain responses to food cues in people with overweight ...
Janne R Hingst, Christa Broholm
exaly   +2 more sources

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Diabetes, Obesity and Metabolism
ABSTRACT Background Obesity is a complex chronic disease requiring effective long‐term management. We performed a systematic review and meta‐analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity.
Saad Ahmed Waqas, Shaheer Bin Shafiq
exaly   +3 more sources

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Journal of Diabetes and Metabolic Disorders
Laksh kumar, Harmain Muhammad asif, Adarsh Raja   +2 more
exaly   +2 more sources